Rival to follow Leo Pharma into biologics segment
Swiss dermatology group Galderma has followed the lead of its Danish rival Leo Pharma and has struck a deal for the rights to a biological drug to treat skin disease.
BY MARTIN HAVTORN PETERSEN
New biological drugs have begun population various areas of the global drug market in recent years, forcing old chemical varieties to play second fiddle. The threat from biologics have been looming as a dark cloud over the dermatology segment as well, but so far the major transition has yet to happen.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Leo Pharma in EUR 675 million acquisition
For abonnenter
Leo Pharma closes massive dermatology deal
For abonnenter
